Lexicon Pharma (LXRX) Tops Q4 EPS by 21c

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.31), $0.21 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $23 million versus the consensus estimate of $15.64 million.

As of December 31, 2016, Lexicon had $346.5 million in cash and investments, as compared to $395.6 million as of September 30, 2016 and $521.4 million as of December 31, 2015.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Sysco raises mid-term targets, unveils $500M AI efficiency program
• The Children's Place (PLCE) PT Lowered to $3.25 at UBS on Soft Sales Trends